The artificial lung devices market covers technologies that temporarily take over or assist the lungs’ gas‑exchange function, most notably extracorporeal membrane oxygenation (ECMO) systems and emerging portable or implantable artificial lungs. These devices are used when conventional ventilation is insufficient or when lung recovery or transplant bridging is needed.

The market was estimated at around USD 5.74 billion in 2023, about USD 6.4 billion in 2024, and is projected to reach roughly USD 15.4 billion by 2032, growing at a CAGR of approximately 11.59%. Growth is driven by rising prevalence of respiratory diseases (COPD, ARDS, severe pneumonia), increasing use of ECMO in critical care, and technological advances in membrane materials, pump systems, and portable designs.wiseguyreports

Respiratory failure is the largest application segment, reflecting the core role of artificial lungs in supporting patients with severe hypoxemia or hypercapnia when mechanical ventilation fails or is contraindicated. Cardiopulmonary bypass (CPB) is another major application, especially in complex cardiac surgeries where temporary oxygenation and circulation are required. ECMO use in ICUs, emergency departments, and transport scenarios is expanding, supported by better training, protocols, and device reliability.wiseguyreports

By type, membrane artificial lungs dominate due to superior gas‑exchange efficiency and suitability for prolonged support. Bubble artificial lungs are used in specific settings and are noted for lower cost and rapid deployment in emergencies, while liquid artificial lungs remain largely experimental but hold long‑term promise for more physiologic oxygenation. Materials such as polypropylene, polyurethane, and polyethylene are widely used for their biocompatibility, durability, and resistance to heat and chemicals.wiseguyreports

Hospitals are the primary end users, given the need for specialized teams, monitoring, and infrastructure. Ambulatory surgery centers and other settings contribute as procedures and technologies evolve. Regionally, North America leads due to advanced critical care capacity, high disease burden, and strong R&D. Europe follows, while Asia‑Pacific is expected to grow fastest as ICU capacity, training, and reimbursement improve. Key players include Medtronic, Getinge, Terumo, LivaNova, Abiomed, and others, with innovation focused on miniaturization, portability, and integration with monitoring and AI‑assisted management.

Read more: Artificial Lung Devices Market: A Comprehensive Analysis 2032

People Also Ask

Q1. What conditions are treated with artificial lung devices?
They are primarily used for severe respiratory failure (e.g., ARDS, COPD exacerbations, severe pneumonia), as rescue therapy when ventilation fails, and as bridge‑to‑recovery or bridge‑to‑transplant in selected patients. They are also used during complex cardiac surgeries via cardiopulmonary bypass.

Q2. Are artificial lungs portable?
Traditional ECMO systems are large and hospital‑based, but newer portable and miniaturized systems are emerging, enabling intra‑hospital transport and, in some cases, inter‑facility transfer. Fully implantable or wearable artificial lungs remain in development.

Tags: artificial lung devices, ECMO, respiratory failure, cardiopulmonary bypass, critical care, extracorporeal life support